商业CAR-T对比替代疗法治疗复发难治性DLBCL的结局
单中心回顾性观察研究纳入215例复发难治性弥漫大B细胞淋巴瘤患者,比较商业CAR-T(69例)与替代疗法(146例)的结局。CAR-T组完全缓解率52%对22%(P<.001),中位无进展生存5.2对2.3个月(P=.01),中位总生存19.3对6.5个月(P=.006)。调整不利基线特征后总缓解率优势仍显著,但PFS和OS差异不再显著;替代疗法缓解者的缓解持续时间与CAR-T缓解者相当。
要点
- CAR-T组完全缓解率52%对22%,中位PFS 5.2对2.3个月,中位OS 19.3对6.5个月。
- 调整不利基线特征后,CAR-T组总缓解率优势仍显著,但PFS和OS差异不再显著。
- 替代疗法缓解者的缓解持续时间与CAR-T缓解者相当,部分场景替代疗法可能同样有效。
核心结论
- 在真实世界复发难治性DLBCL中,商业CAR-T较替代疗法提高完全缓解率、PFS和OS。
- 调整不利基线特征后仅总缓解率优势仍显著,PFS和OS差异不再显著。
- 对替代疗法有缓解的患者可获得与CAR-T缓解者相当的持久缓解,部分临床场景替代疗法可能同样有效。
研究设计与样本
- 单中心、回顾性、观察性研究,共纳入215例复发难治性DLBCL患者。
- CAR-T组69例,历史对照的替代疗法组146例。
主要发现
- CAR-T组与替代疗法组完全缓解率分别为52%与22%(P<.001)。
- 中位无进展生存分别为5.2个月与2.3个月(P=.01)。
- 中位总生存分别为19.3个月与6.5个月(P=.006)。
- 该生存优势似乎不受既往治疗线数影响。
- 调整不利预处理疾病特征后,CAR-T组总缓解率优势仍显著,但PFS和OS差异不再显著。
关键数值与推荐
- CAR-T获批用于既往≥2线治疗后的复发难治性DLBCL,基于单臂2期试验,完全缓解率40%至60%。
- 本研究CAR-T组完全缓解率52%,替代疗法组22%(P<.001)。
- 本研究CAR-T组中位PFS 5.2个月、中位OS 19.3个月;替代疗法组分别为2.3个月和6.5个月。
临床怎么用
- 商业CAR-T在真实世界复发难治性DLBCL中可提高缓解率和生存,但需结合基线特征解读。
- 对替代疗法有缓解的患者缓解可持续较久,特定临床场景可考虑替代疗法。
- 尚需随机前瞻性试验验证CAR-T与替代疗法的相对疗效。
局限性
- 单中心、回顾性、观察性研究,CAR-T组与历史对照替代疗法组比较。
- 调整不利预处理疾病特征后PFS和OS差异不再显著,提示存在混杂。
- 样本量有限(CAR-T组69例,替代疗法组146例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R DLBCL after 2 prior lines of therapy based on data from single-arm phase 2 trials, with complete responses (CRs) in 40% to 60% of patients. However, a direct comparison with other treatments is not available and, moreover, its true efficacy in real-world patients is unknown. In this single center, retrospective, observational study of 215 patients, we compared outcomes in patients treated with CAR T-cell therapy (n = 69) with a historical population treated with alternate therapies (n = 146). Patients treated with CAR T cell vs alternate therapies demonstrated a CR rate of 52% vs 22% (P < .001), median progression-free survival (PFS) of 5.2 vs 2.3 months (P = .01), and median overall survival (OS) of 19.3 vs 6.5 months (P = .006), and this advantage appeared to persist irrespective of the number of lines of prior therapy. After adjusting for unfavorable pretreatment disease characteristics, superior overall response rate in the CAR T cohort remained significant; however, differences in PFS and OS between cohorts did not. In addition, patients who responded to alternate therapies demonstrated prolonged remissions comparable to those who responded to CAR T therapy. We contend that in select clinical scenarios alternate therapies may be as efficacious as CAR T therapy; thus, additional study is warranted, ideally with randomized prospective trials.
引用
- Sermer D, Batlevi C, Palomba ML, et al. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv. 2020. PMID: 33002134. doi:10.1182/bloodadvances.2020002118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。